JMP Securities Downgrades Achillion Pharmaceuticals To Market Perform

Loading...
Loading...
Analysts at JMP Securities downgraded
Achillion Pharmaceuticals, Inc.ACHN
from Market Outperform to Market Perform and removed the price target of $24.00. Achillion Pharmaceuticals shares have gained 292.65 percent over the past 52 weeks, while the S&P 500 index has surged 12.70 percent in the same period. Achillion Pharmaceuticals' shares fell 8.71 percent to9.75 in pre-market trading.
Posted In: DowngradesAnalyst RatingsJMP Securities
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...